Medical/Pharmaceuticals
Laekna Therapeutics Appoints Jeff Porter, Ph.D. as Chairman of Scientific Advisory Board
SHANGHAI and WARREN, N.J., March 29, 2022 /PRNewswire/ -- Laekna Therapeutics, a clinical-stage global biotechnology company，announced today the appointment of Jeff Porter, Ph.D. as the Chairman of its Scientific Advisory Board (SAB). Dr. Porter has over 25 years of global R&D leadership and strat...
2022-03-29 20:00
2098
New Video Series "PSMA PET/CT TODAY" Discusses the Future of Prostate Cancer Care with Leading Experts
MELBOURNE, Australia and INDIANAPOLIS, March 29, 2022 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces the launch of PSMA PET/CT[1] Today, a five-part video series, featuring leading theranostics experts, on the role of advanced diagnostic imaging in pr...
2022-03-29 19:00
2297
I-Mab Provides Business and Corporate Updates and Reports Financial Results for the Year Ended December 31, 2021
* Financial results demonstrate strong fundamentals * Twenty key clinical milestones achieved year-to-date, including positive data readouts for lemzoparlimab, uliledlimab and felzartamab * Seven business development deals, including a US$315M strategic commercial partnership with Jumpcan on...
2022-03-29 18:10
3430
Nippon Express (Middle East) Becomes First Japanese Logistics Company to Acquire GDP Certification in Middle East
TOKYO, March 29, 2022 /PRNewswire/ -- Nippon Express (Middle East) L.L.C. (hereinafter "NX Middle East"), a group company of Nippon Express Holdings, Inc., onFebruary 3, 2022, became the first Japanese logistics company in the Middle East to obtain Good Distribution Practice (GDP) certification f...
2022-03-29 14:00
1869
Samsung Biologics holds 11th Annual General Meeting of Shareholders
INCHEON, South Korea, March 28, 2022 /PRNewswire/ -- Samsung Biologics (KRX: 207940.KS), the world's leading contract development and manufacturing organization (CDMO), hosted its 11th Annual General Meeting of Shareholders (AGM)today. Five matters were presented and approved unanimously at this ...
2022-03-29 09:42
2844
VolitionRx Limited Schedules Full Fiscal Year 2021 Earnings Conference Call and Business Update
Conference call to take place on Thursday March 31 at 08:00a.m. Eastern time AUSTIN, Texas, March 28, 2022 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced it will host a conference call on Thursday March 31, 08.00a.m. Eastern time to discuss its financial and ...
2022-03-29 04:25
2706
Viva Biotech Announced 2021 Annual Results: Revenue Increased by 201.9% YoY, CRO Business Revenue Maintained Rapid Growth with an Increase of 68.7%
Financial Highlights of the year ended December 31, 2021: * Revenue amounted to RMB2,104.1 million, representing a year-on-year (YoY) increase of 201.9% * Gross profit amounted to RMB651.0 million, representing a YoY increase of 113.5% * Adjusted Non-IFRS net profit amounted to RMB352.5 mil...
2022-03-29 00:49
3557
Clarity's US-based Cu-64 SAR-bisPSMA trial in prostate cancer opens for recruitment
SYDNEY, March 28, 2022 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity"), a clinical-stage radiopharmaceutical company developing next-generation products to address the growing needs in oncology, is pleased to announce that the diagnostic 64Cu SAR-bisPSMA trial (COBRA NCT05249127 <...
2022-03-28 21:06
2572
First-ever integrated EEG and neurotherapeutics device iSyncWave wins the 2022 Red Dot Design Award
SEOUL, South Korea, March 28, 2022 /PRNewswire/ -- AI-based digital mental
healthcare platform company iMediSync has announced that their product
"iSyncWave" has won the 2022 Red Dot Design Award for its innovative and
creative design asa dry EEG headset.
2022-03-28 20:00
2967
Tigermed Reports Strong 2021 Full-Year Results
HANGZHOU, China, March 28, 2022 /PRNewswire/ -- Hangzhou Tigermed Consulting Co., Ltd. ("Tigermed" or the "company") (Stock code: 300347.SZ / 3347.HK), a leading provider of clinical research solutions across full lifecycle of global biopharmaceutical and medical device products, announced its an...
2022-03-28 19:10
3516
At the 2022 AAD Annual Meeting, Senhwa Presents Positive Initial Data from Clinical Trial of Silmitasertib Used to Treat Patients with Advanced Basal Cell Carcinoma
* Early results showed 2 laBCC (locally advanced Basal Cell Carcinoma) subjects out of 10 experienced a Partial Response (30% decrease in tumor size) at week #24. * The first biopsy analysis in the laBCC subject showed a more than 90% decrease of GLI-1 expression at week #8 (GLl-1 is involved...
2022-03-28 19:00
2556
InnoCare Announces Approval of Clinical Trial of TYK2 JH2 Allosteric Inhibitor ICP-488 in China
BEIJING, March 27, 2022 /PRNewswire/ -- InnoCare Pharma (HKEX: 09969) announced today that the company has received Investigational New Drug (IND) approval of clinical trial from the NMPA (National Medical Products Administration) for its TYK2 JH2 allosteric inhibitor ICP-488, which is the Compan...
2022-03-28 10:48
2388
Kintor Pharma Announces 2021 Business Progress and Annual Results
SUZHOU, China, March 25, 2022 /PRNewswire/ -- Kintor Pharmaceutical Limited (Kintor Pharma, HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecules and biological therapeutics, today announced business highlights and financial results for the year endedDecember 3...
2022-03-26 01:23
8604
Harbour BioMed Reports Full Year 2021 Financial Results: Empower Value Creation with Global Innovation Capabilities
CAMBRIDGE, Mass. and ROTTERDAM, Netherlands and SUZHOU, China, March 24, 2022 /PRNewswire/ --Harbour BioMed ("HBM" or the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery, development and commercialization of novel antibody therapeutics focusing on oncology a...
2022-03-25 10:22
3877
New clinical trial collaboration for Cu-64 SAR-bisPSMA in prostate cancer
SYDNEY, March 24, 2022 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity"), a clinical-stage radiopharmaceutical company developing next-generation products to address the growing needs in oncology, is pleased to announce that an investigator-initiated trial (IIT) will commence shortly...
2022-03-24 21:08
2661
CARsgen Announces First Patient Enrollment in the Confirmatory Phase II Clinical Trial of CT041 in China
SHANGHAI, March 23, 2022 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T cell therapies for the treatment of hematologic malignancies and solid tumors, today announced that CT041, an autologous CAR T-cell product candidate against...
2022-03-23 20:50
2611
CARsgen 2021 Annual Results: Steady Advancement in Innovative CAR T Products and Technologies
SHANGHAI, March 23, 2022 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T cell therapies for the treatment of hematologic malignancies and solid tumors, announced its 2021 Annual Results. Business Highlights * CT053: complete...
2022-03-23 20:50
4504
Smartee Raises US$ 80 Million in Series D Funding
BEIJING, March 23, 2022 /PRNewswire/ -- In March 2022, Smartee announced that it has closed its Series D funding round ofUS$ 80 million. This round of financing was led by Beijing Taikang Investment, followed by China Resources Consumer Fund II, Jiaxing Science City, Zhangjiagang Industrial Inves...
2022-03-23 20:40
3342
InnoCare Releases 2021 Annual Results and Business Highlights
BEIJING, March 22, 2022 /PRNewswire/ -- InnoCare Pharma (HKEX: 09969), a leading biopharmaceutical company focusing on cancer and autoimmune diseases, today announced 2021 annual results as of31 December 2021. Dr. Jasmine Cui, Co-founder, Chairwoman and CEO of InnoCare, said, "We are delighted ...
2022-03-23 08:08
4028
VivaVision Biotech Announces Positive Topline Results of VVN001 in the Phase 2 Clinical Study for the Treatment of Dry Eye Disease
SHANGHAI, March 22, 2022 /PRNewswire/ -- VivaVision Biotech, Inc. (VivaVision), an ophthalmic pharmaceutical developer focusing on discovery and development of innovative therapies for ocular diseases, today announced positive topline results from a Phase 2 clinical study of VVN001 in patients wi...
2022-03-23 08:00
2605
Week's Top Stories
Most Reposted
HLB's Flagship CIO Fund Launched with Strategic Alliance with Lombard Odier
[Picked up by 281 media titles]
2026-09-28 23:04
Responsible Fintech Institute Appoints Four Executive Fellows and Elevates Distinguished Professor Patrick H. M. Loh to Co-Founder
[Picked up by 279 media titles]
2026-09-29 09:00
Allianz Partners unveils next-generation travel insurance platform to help partners navigate changing landscape
[Picked up by 269 media titles]
2026-09-28 07:30
ViewSonic Launches VG1457 Dual-Screen Portable Monitor for Productivity Anywhere
[Picked up by 267 media titles]
2026-09-30 10:50
Zenika CTO Adrien Nortain Moves Base to Singapore to Strengthen Technical Leadership in Asia
[Picked up by 267 media titles]
2026-10-01 10:00
Most Read
MixVio AI Launches Unified Creative Workspace Across 26 AI Generation Routes
2026-10-02 00:30
22969
